Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product ...

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. Given this risk, we thought we'd take a look at whether Capricor Therapeutics (NASDAQ:CAPR) ...

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Medivir AB, with a price target of SEK54.00. The company’s shares closed yesterday at SEK0.51. Take ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. BOSTON — Replimune Group and ...

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They ...

Capricor Therapeutics (CAPR) shares soared 5.3% in the last trading session to close at $6.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

The winding regulatory road for the BLA to Capricor Therapeutics Inc.’s cell therapy for Duchenne muscular dystrophy has more clarity. Out of a recent type A meeting between Capricor and the U.S. FDA, ...

Capricor Therapeutics is raising issues with the U.S. Food and Drug Administration's new policy of publishing rejection letters sent to drugmakers. The FDA in June began publishing older letters, ...

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR ...